GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Capex-to-Revenue

Waverley Pharma (TSXV:WAVE) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Waverley Pharma's Capital Expenditure for the three months ended in Dec. 2023 was C$0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was C$0.05 Mil.

Hence, Waverley Pharma's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Waverley Pharma Capex-to-Revenue Historical Data

The historical data trend for Waverley Pharma's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Capex-to-Revenue Chart

Waverley Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial - - - - -

Waverley Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Waverley Pharma's Capex-to-Revenue

For the Biotechnology subindustry, Waverley Pharma's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waverley Pharma's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's Capex-to-Revenue falls into.



Waverley Pharma Capex-to-Revenue Calculation

Waverley Pharma's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.412
=0.00

Waverley Pharma's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.049
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Waverley Pharma  (TSXV:WAVE) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Waverley Pharma Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Waverley Pharma (TSXV:WAVE) Business Description

Traded in Other Exchanges
Address
1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Executives
Albert David Friesen 10% Security Holder, Director, Senior Officer

Waverley Pharma (TSXV:WAVE) Headlines

From GuruFocus